Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

rhThrombin enters phase II

April 21, 2004

Eisai describes novel, potent orally active small molecule thrombin receptor antagonists

April 19, 2004

GlaxoSmithKline to acquire Fraxiparine and Arixtra

April 19, 2004

Merck KGaA team presents novel inhibitors of factor Xa and other coagulation factors

April 13, 2004

Novel orally effective PAI-1 inhibitor for fibrinolytic dysfunction

March 30, 2004

PARP inhibitor HO-3089 demonstrates both cardioprotective and antithrombotic potential

March 25, 2004

Transgenomic to manufacture components of regulatable anticoagulant therapy

March 24, 2004

Novel GP IIb/IIIa antagonists from Millennium

March 23, 2004

Two series of factor Xa inhibitors claimed by Boehringer Ingelheim

March 22, 2004

New dabigatran prodrugs designed by Boehringer Ingelheim researchers

March 22, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
Anle-138b reduces mHTT aggregation, improves pathological phenotypes in Huntington’s models
BioWorld Science
Anle-138b (emrusolmin) is a diphenylpyrazole compound that directly interacts with oligomeric species of disease-related aggregating proteins, reducing aggregate...